Apoptosis and cancer chemotherapy

被引:200
作者
Makin, G [1 ]
Hickman, JA [1 ]
机构
[1] Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England
关键词
apoptosis; chemotherapy; drug resistance; p53; Bcl-2; family;
D O I
10.1007/s004419900160
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Apoptosis is a fundamental mechanism of cell death that can be engaged by a range of cellular insults. One of the major modes of action of chemotherapeutic drugs may be via the activation of apoptosis. Understanding how the cell death program is engaged following an insult, and hence why it fails to be engaged in certain settings, offers a novel approach to overcoming the clinical problem of drug resistance. The tumour suppressor gene p53 and its downstream effector genes p21, mdm-2,and gadd45 seem to be important in the cellular response to genotoxic drug induced damage. Considerable evidence has accrued about the effect of mutations of this pathway on drug sensitivity and this is discussed. The expanding Bcl-2 family of proteins also play an important role in the cell death program. Evidence suggests that these proteins may function as integrators of damage signals, and may be the final decision point as to whether a cell lives or dies. These proteins may thus represent a logical target for new approaches to overcoming drug resistance.
引用
收藏
页码:143 / 152
页数:10
相关论文
共 103 条
  • [1] The Bcl-2 protein family: Arbiters of cell survival
    Adams, JM
    Cory, S
    [J]. SCIENCE, 1998, 281 (5381) : 1322 - 1326
  • [2] Bellamy COC, 1997, BRIT MED BULL, V53, P522
  • [3] Stat3 activation is required for cellular transformation by v-src
    Bromberg, JF
    Horvath, CM
    Besser, D
    Lathem, WW
    Darnell, JE
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (05) : 2553 - 2558
  • [4] Brown JM, 1999, CANC DRUG DISC DEV, V5, P1
  • [5] Brown JM, 1999, CANCER RES, V59, P1391
  • [6] Brown R, 1997, BRIT MED BULL, V53, P466
  • [7] Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers
    Brunet, CL
    Gunby, RH
    Benson, RSP
    Hickman, JA
    Watson, AJM
    Brady, G
    [J]. CELL DEATH AND DIFFERENTIATION, 1998, 5 (01) : 107 - 115
  • [8] Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
    Budman, DR
    Berry, DA
    Cirrincione, CT
    Henderson, IC
    Wood, WC
    Weiss, RB
    Ferree, CR
    Muss, HB
    Green, MR
    Norton, L
    Frei, E
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (16) : 1205 - 1211
  • [9] P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES
    CAELLES, C
    HELMBERG, A
    KARIN, M
    [J]. NATURE, 1994, 370 (6486) : 220 - 223
  • [10] Campbell SJ, 1999, CANC DRUG DISC DEV, V5, P53